Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Zum ersten Bild Abb. 5: Morgendliche Blutdrucksenkung Abb. 6: Morgendliche Blutdrucksenkung - Angiotensin-I-Rezeptorblocker Abb. 7: Telmisartan - Losartan Aktuelles Bild - Abb. 8: Telmisartan - Losartan Abb. 9: Telmisartan - Losartan Abb. 10: Telmisartan - Losartan Abb. 11: Telmisartan - Losartan - Studienverlauf Zum letzten Bild
Abbildung 8: Telmisartan - Losartan
The two fixed-dose studies comparing low doses of telmisartan and losartan also found telmisartan to be superior in 24-h mean ambulatory blood pressure reductions. Mallion et al. recruited 223 patients with mild-to-moderate hypertension for a 6-week trial of telmisartan 40 mg or 80 mg and losartan 50 mg.1 Telmisartan 40 mg gave significantly superior reductions in SBP and DBP. The reduction in 24-h mean SBP was 11.5 mmHg with telmisartan 40 mg and 8.0 mg with losartan 50 mg (p<0.05). Telmisartan 80 mg was also superior to losartan 50 mg. Ding et al. compared telmisartan 40 mg with losartan 50 mg in 56 Taiwanese patients with mild-to-moderate hypertension.2 The reduction in 24-h mean DBP was superior with telmisartan compared with losartan. Reductions in 24-h mean SBP (14.6 mmHg with telmisartan and 11.2 mmHg with losartan) did not reach statistical significance. 1. Mallion JM, et al. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657–664. 2. Ding PY, et al. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl 2004; 58: 16–22.
 
Telmisartan - Losartan
Vorheriges Bild Nächstes Bild   


Abbildung 8: Telmisartan - Losartan
The two fixed-dose studies comparing low doses of telmisartan and losartan also found telmisartan to be superior in 24-h mean ambulatory blood pressure reductions. Mallion et al. recruited 223 patients with mild-to-moderate hypertension for a 6-week trial of telmisartan 40 mg or 80 mg and losartan 50 mg.1 Telmisartan 40 mg gave significantly superior reductions in SBP and DBP. The reduction in 24-h mean SBP was 11.5 mmHg with telmisartan 40 mg and 8.0 mg with losartan 50 mg (p<0.05). Telmisartan 80 mg was also superior to losartan 50 mg. Ding et al. compared telmisartan 40 mg with losartan 50 mg in 56 Taiwanese patients with mild-to-moderate hypertension.2 The reduction in 24-h mean DBP was superior with telmisartan compared with losartan. Reductions in 24-h mean SBP (14.6 mmHg with telmisartan and 11.2 mmHg with losartan) did not reach statistical significance. 1. Mallion JM, et al. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657–664. 2. Ding PY, et al. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl 2004; 58: 16–22.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung